Sign up USA
Proactive Investors - Run By Investors For Investors

Summit Therapeutics PLC's ridinilazole results continue to impress

Shares in Summit Therapeutics went higher as it revealed its new antibiotic for hospital superbug C.Diff could treat the disease and help stop it reoccurring.
Summit Therapeutics PLC's ridinilazole results continue to impress
Clostridium difficile, or C-diff, is a big threat in hospitals and care homes...

Shares in Summit Therapeutics PLC (NASDAQ: SMMT, LON: SUMM) went higher as it revealed its new antibiotic for hospital superbug C.Diff could treat the disease and help stop it reoccurring.

The further positive data comes from the CoDIFy Phase 2 clinical trial  and showed that ridinilazole can preserve the micobiome in the gut as it treats the condition, while the standard of care medicine - vancomycin - causes "substantial and long-lasting damage" on the microbiome, or the eco-system of the gut.

Clostridium difficile, or C-diff, is caused after damage to the microbiome but patients can get a double whammy, as using broad spectrum antibiotics can further damage the microbiome.

Glyn Edwards, chief executive of Summit, told investors: "These new results from the Phase 2 trial show ridinilazole preserves the patients' microbiome while simultaneously working to eradicate the C. difficile bacteria.

"The clinical data strongly suggest that ridinilazole treatment may be better able to protect against recurrent disease than the current standard of care.

"We believe this approach offers a clear advantage over conventional broad spectrum antibiotics currently used to treat CDI that cause substantial damage to the gut microbiome or approaches that aim to artificially re-establish a damaged gut microbiome following antibiotic treatment."

Summit reckons ridinilazole could become a single therapeutic approach capable of both treating the initial infection and reducing the high rates of recurrent disease.

Today's findings come after recently reported results from the Phase 2 CoDIFy trial that showed ridinilazole to be statistically superior to vancomycin in sustained clinical response.

C. diff is a serious threat in hospitals and care homes and there are between 450,000 and 700,000 cases in the US annually.

It is caused by an infection of the colon by the bacterium C. difficile, which produces toxins that causes inflammation, severe diarrhoea and in the most serious cases can be fatal.

Biopharma Summit, listed in London and New York, as well as C-diff, is focused on developing a treament for Duchenne muscular dystrophy.

Shares advanced in London 4.55% to 103.5p.

Giles_55af4ddca6481.jpg


Register here to be notified of future SUMM Company articles
View full SUMM profile

Summit Therapeutics PLC Timeline

Related Articles

Magnified view of cancer cells
July 28 2016
ANGLE's Parsortix blood screening system could replace the traditional biopsy in the diagnosis of breast cancer. Proactive takes a look at how it works and the potential it holds to change the way cancer is diagnosed.
bathroom-scale-1149265.jpg
November 29 2016
The focus initially will be previously-approved indications for adolescent obesity along with new treatment areas non-alcoholic fatty liver disease and for non-alcoholic steatohepatitis
antibiotic.jpg
March 02 2016
In all 1,200 patients will take part in the global trials run by Motif’s partner Covance.
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC